Of note, the number of CD45+/FSP-1+ cells in the bevacizumab-treated patients was significantly correlated with the number of treatment cycles of bevacizumab (Fig. 8i) and with the vessel length in the tumour (Fig. 8j). Here, PTPRC is linked to neoplasm.